Analyst Price Targets — PCVX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 7:27 pm | Tom Shrader | BTIG | $89.00 | $63.04 | StreetInsider | Vaxcyte (PCVX) PT Raised to $89 at BTIG |
| November 19, 2025 10:23 am | David Risinger | Leerink Partners | $77.00 | $49.53 | StreetInsider | Vaxcyte (PCVX) PT Raised to $77 at Leerink Partners |
| November 6, 2024 11:13 am | Roger Song | Jefferies | $146.00 | $106.74 | StreetInsider | Vaxcyte (PCVX) PT Raised to $146 at Jefferies |
| November 6, 2024 10:59 am | David Risinger | Leerink Partners | $135.00 | $106.74 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX) |
| September 10, 2024 6:46 am | Salim Syed | Mizuho Securities | $163.00 | $115.28 | TheFly | Vaxcyte price target raised to $163 from $113 at Mizuho |
| September 4, 2024 6:34 am | Jason Gerberry | Bank of America Securities | $140.00 | $110.15 | TheFly | Vaxcyte price target raised to $140 from $101 at BofA |
| September 3, 2024 2:34 pm | David Risinger | Leerink Partners | $153.00 | $112.04 | TheFly | Vaxcyte price target raised to $153 at Leerink after VAX-31 'home run' |
| September 3, 2024 11:48 am | Tom Shrader | BTIG | $160.00 | $110.15 | StreetInsider | Vaxcyte (PCVX) PT Raised to $160 at BTIG |
| September 3, 2024 9:33 am | Roger Song | Jefferies | $129.00 | $111.13 | StreetInsider | Vaxcyte (PCVX) PT Raised to $129 at Jefferies |
| September 3, 2024 8:25 am | Salim Syed | Mizuho Securities | $113.00 | $111.09 | StreetInsider | Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX) |
Latest News for PCVX
Citigroup Inc. reduced its stake in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 27.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 313,078 shares of the company's stock after selling 116,206 shares during the period. Citigroup Inc. owned approximately 0.24% of Vaxcyte worth $11,277,000 as
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027 Enrollment Completed in VAX-31 Infant Phase 2 Dose-Finding Study; Topline…
China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ: PCVX) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,756 shares of the company's stock after selling 9,154 shares during
Vaxcyte (NASDAQ: PCVX) executives used a presentation at an annual biotech summit to highlight progress across the company's pneumococcal conjugate vaccine (PCV) pipeline, with a particular focus on its 31-valent candidate, VAX-31, and the Phase 3 adult program now underway. Focus on pneumococcal conjugate vaccines and broader coverage Chief Executive Officer Grant Pickering said Vaxcyte has
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PCVX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.